Author_Year,Country,Study_Design,Intervention_Denosumab,Control_N,Age≥18,OP_only,Route_SC_only,Control_Group_None,Sample_N≥100,Invasive_Procedure_Documented,FollowUp≥6m,MRONJ_Incidence_Reported,Latency_Documented,Eligibility,Reason_for_Exclusion
Everts‑Graber 2022,Switzerland,Retrospective registry cohort,≈3 068 pts / 4 236 patient‑years,None (vs BP only),Yes,Yes,Yes,Yes (so fails),Yes,"No (general ONJ, triggers varied)",Yes,Yes (12 cases),No,Exclude,No anti‑resorptive‑free control; MRONJ not limited to post‑procedure
Wei 2025,Taiwan,Retrospective cohort of dental extractions,≈276 pts / 376 extractions,None,Yes,Yes,Yes,Yes,Yes,Yes (tooth extractions),Yes,Yes (21 cases),Drug duration & interruption but not procedure→ONJ,Exclude,No medication‑naïve control
Kwack & Park 2023,Korea,Retrospective prediction‑model dataset,Subset of 340 pts (exact N NR),None,Yes (≥55),Yes,Yes,Yes,Yes,Yes (extraction / implant),Yes,Yes (overall 130 cases),No,Exclude,No medication‑naïve control; mixed AR classes
Watts 2019,Multinational,Extension of RCT (open‑label denosumab),"≈4 550 pts, 7 yrs exposure",Placebo only first 3 y (no OPE data),Yes,Yes (post‑meno women),Yes,Yes (during OL),Yes,Yes (OPE survey),Yes (10 y),Yes (13 cases),Partial (time inciting event→ONJ),Exclude,No concurrent medication‑naïve control group
